How do you prioritize treatment in a lung cancer patient who has HER2 IHC3+ along with other actionable mutations that have tumor-specific drugs available?
How would you prioritize treatment in NSCLC with HER2 IHC3+ and treated for another actionable mutation (e.g., EGFR, ALK, ROS1) in first line?
Join Mednetto vote and see how they answered.
Non-small cell lung cancer (NSCLC) can harbor different HER2 alterations: HER2 protein overexpression (2-35%), HER2 gene amplification (2-20%), and HER2 gene mutations (1-4%). Unlike breast or gastric cancer, HER2 protein overexpression in NSCLC is not a validated biomarker for first-line HER2-targe...
Join for free or sign in to see the full answer
For all cancers, it is important to balance the expected antitumor activity of agents with tumor-specific approvals as well as adverse event profiles to personalize treatment choice and sequence of therapies.
Join for free or sign in to see the full answer
Non-small cell lung cancer (NSCLC) can harbor different HER2 alterations: HER2 protein overexpression (2-35%), HER2 gene amplification (2-20%), and HER2 gene mutations (1-4%). Unlike breast or gastric cancer, HER2 protein overexpression in NSCLC is not a validated biomarker for first-line HER2-targe...
Join for free or sign in to see the full answer